They introduce an innovative strategy for enhancing breast cancer immunotherapy by precisely degrading HER2 protein through peptide‐conjugated PDT, which can be used as a case study for nanozyme‐mediated breast cancer treatment. Here, ERBB2 is linked to breast cancer.